Work

Virologic Response, Early HIV-1 Decay, and Maraviroc Pharmacokinetics With the Nucleos(t)ide-Free Regimen of MaravIroc Plus Darunavir/Ritonavir in a Pilot Study

Year: 2020

Type: article

Abstract: To address the need for nucleos(t)ide reverse transcriptase inhibitor (NRTI)-sparing regimens, we explored the virologic and pharmacokinetic characteristics of maraviroc plus ritonavir-boosted darunavir in a single-arm, open-label, 96-week study.

Source: Carolina Digital Repository (University of North Carolina at Chapel Hill)

DOI: 10.17615/xc04-tt35

Authors: Swindells, Susan, Lalezari, Jay, Acosta, Edward P., Taiwo, Babafemi, Lu, Darlene, Adeyemi, Oluwatoyin, Eron, Joseph J., Kuritzkes, Daniel R., Castro, Jose, Tsibris, Athe, Berzins, Baiba, Ryscavage, Patrick

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Pfizer, University of Miami, Northwestern University

OpenAlex ID: W4299575966

FWCI:

Cites:

Cited by:

Related to: 10